尽管软组织肉瘤（STS）的发病率较低，但全球每年仍有数十万例新的STS病例被诊断出来，其中大约有一半最终进展至晚期。目前，化疗是晚期STS的一线治疗方法。在多线化疗的选择途径上存在困难，或者对不同STS组织学亚型的联合治疗选择药物困难。本研究首先全面评估了各种化疗药物在STS治疗中的疗效，并描述了不同STS亚型敏感药物的现状。蒽环类药物是晚期STS最重要的全身治疗药物。伊福沙胺、特贝曲丁、吉西他滨、紫杉醇、达卡巴嗪和厄立白都对STS具有一定的活性。长春新碱类药物（长春碱、长春ci，长春碱胺碱、长春碱）在特定的STS亚型，如横纹肌肉瘤和Ewing肉瘤家族瘤中具有重要的治疗作用，而在其他亚型中的活性较弱。其他化疗药物（甲氨蝶呤、顺铂、依托泊苷、喷细胞龙）对STS的疗效较弱，很少使用。根据组织学亚型选择特定的二线或以上化疗药物是必要的。这篇综述旨在为对晚期STS患者进行多线治疗时选择化疗药物提供参考，因其存活时间逐渐延长。版权所有 © 2023 Tian and Yao.

Despite the low incidence of soft tissue sarcomas (STSs), hundreds of thousands of new STS cases are diagnosed annually worldwide, and approximately half of them eventually progress to advanced stages. Currently, chemotherapy is the first-line treatment for advanced STSs. There are difficulties in selecting appropriate drugs for multiline chemotherapy, or for combination treatment of different STS histological subtypes. In this study, we first comprehensively reviewed the efficacy of various chemotherapeutic drugs in the treatment of STSs, and then described the current status of sensitive drugs for different STS subtypes. anthracyclines are the most important systemic treatment for advanced STSs. Ifosfamide, trabectedin, gemcitabine, taxanes, dacarbazine, and eribulin exhibit certain activities in STSs. Vinca alkaloid agents (vindesine, vinblastine, vinorelbine, vincristine) have important therapeutic effects in specific STS subtypes, such as rhabdomyosarcoma and Ewing sarcoma family tumors, whereas their activity in other subtypes is weak. Other chemotherapeutic drugs (methotrexate, cisplatin, etoposide, pemetrexed) have weak efficacy in STSs and are rarely used. It is necessary to select specific second- or above-line chemotherapeutic drugs depending on the histological subtype. This review aims to provide a reference for the selection of chemotherapeutic drugs for multi-line therapy for patients with advanced STSs who have an increasingly long survival.Copyright © 2023 Tian and Yao.